Low-Profile High-Density Braid Occluder for Treatment of Pulmonary Arteriovenous Malformations

Tuesday, April 14, 2026

3:45 PM - 3:54 PM ET

Location: 718B

Presenting Author(s)

AP

Anmol B. Patel, MD

IR/DR Resident
University of Chicago Hospital, United States

Author/Co-author(s)

Qian Yu, MD (he/him/his)

Resident
University of Chicago, United States
Ed

Elise de Bruyn, MD

PGY4 IR-Integrated Resident
University of Chicago, United States
LL

Luis Landeras, MD

Associate Professor
University of Chicago, United States
Steven Zangan, MD

Associate Professor
University of Chicago, United States
BF

Brian Funaki, MD, FSIR

Professor of Radiology
University of Chicago, United States

Purpose: To evaluate the safety and efficacy of a low-profile braided occluder (LOBO; Okami Medical, San Diego, California) for embolization of pulmonary arteriovenous malformations (PAVMs).

Materials and Methods: A single-institutional retrospective review was conducted from January 2022 to September 2025. Adult patients with PAVMs treated using the LOBO device were included. After excluding 4 patients and 5 PAVMs without radiologic follow-up, a total of 14 patients (mean age: 42.9 ± 15.9 years) with 22 PAVMs were included. Technical success, radiologic response (defined as >70% reduction in lesion size), and clinical outcomes were evaluated.

Results: Twenty (90.9%) had a single feeding artery; the remaining 2 (9.1%) were complex with multiple feeders. The mean feeding artery diameter was 3.3 ± 1.1 mm, and the mean PAVM size was 11.0 ± 5.1 mm. A total of 26 occluders were deployed into the feeder pulmonary arteries (LOBO-3: n=16; LOBO-5: n=10), achieving complete cessation of flow by end of procedures with a technical success was of 100%. No major complications occurred. Over a mean CT follow-up period of 13.3 ± 14.1 months (1-year follow-up: n=11; 3-year follow-up: n=4), no cases of PAVM persistence or device migration were observed. During a mean clinical follow-up of 19.6 ± 15.3 months, no catastrophic events occurred.

Conclusion: Mid-term outcomes suggest that the LOBO device is a safe and effective option for the treatment of PAVMs.